Lipocine (LPCN) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lipocine (LPCN) has outperformed NewcelX (NCEL) over the past year, losing 38.9% versus a loss of 83.3%. Over five years, LPCN leads with a -90.0% price change compared with -99.7% for NCEL. NewcelX is the larger company by market cap ($17.6 million vs $14.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LPCN | NCEL |
|---|---|---|
| Share price | $1.73 | $3.05 |
| Market cap | $14.26M | $17.59M |
| 1-day change | -10.37% | -2.09% |
| YTD return | -75.97% | +63.68% |
| 1-year return | -38.92% | -83.32% |
| 5-year return | -89.95% | -99.68% |
| P/E ratio (TTM) | — | 5.86 |
| EPS (TTM) | $-1.85 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.37 | $18.60 |
| 52-week low | $1.73 | $1.83 |
| Distance from 52-week high | -86.02% | -83.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +189.03% | +655.34% |
| Average volume | 1.72M | 10.28K |
| Shares outstanding | 8.24M | 5.78M |
| Employees | 14 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed NCEL by 44.4 percentage points over the past year.
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
LPCN vs NCEL FAQ
Which is bigger, Lipocine or NewcelX?
NewcelX (NCEL) is larger, with a market capitalization of $17.59M compared with $14.26M for Lipocine (LPCN).
Which stock has performed better over the past year, LPCN or NCEL?
LPCN returned -38.92% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are Lipocine and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.